← All diseases
Lungs and airways
Pulmonary fibrosis (IPF)
Would you like to receive a message when there is new research on Idiopathic Pulmonary Fibrosis (IPF)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above each publication you'll find one sentence explaining what was researched — and you'll receive a notification as soon as there is new research on Pulmonary Fibrosis (IPF). View what Premium costs.
Publications and studies (1942)
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide (2025-03-05) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Evaluation of the Value of 18F-Fluoromisonidazole (18F-FMISO) Positron Emission Tomography Hypoxia Imaging in Idiopathic Pulmonary Fibrosis (2025-03-04) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib (2025-02-18) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. BUILD 3: Bosentan Use in Interstitial Lung Disease (2025-02-04) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 (2025-02-04) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT (2025-02-04) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma (2025-02-03) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis (2025-01-31) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects (2025-01-31) ♡
- Mortality-related risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. (2024/12/31) ♡
- Impact of antifibrotic therapy on lung cancer incidence and mortality in patients with idiopathic pulmonary fibrosis. (2024/12/31) ♡
- Current status of pulmonary rehabilitation and impact on prognosis of patients with idiopathic pulmonary fibrosis in South Korea. (2024/12/31) ♡
- SOCS domain targets ECM assembly in lung fibroblasts and experimental lung fibrosis. (2024/12/30) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Anti-PL-7/PL-12 antisynthetase syndrome associated with interstitial lung disease following SARS-COV-2 infection and vaccination: A case study review. (2024/12/30) ♡
- The density histograms-derived computerized integrated index (CII) predicts mortality in idiopathic pulmonary fibrosis. (2024/12/28) ♡
- Inhalable Carbonyl Sulfide Donor-Hybridized Selective Phosphodiesterase 10A Inhibitor for Treating Idiopathic Pulmonary Fibrosis by Inhibiting Tumor Growth Factor-β Signaling and Activating the cAMP/Protein Kinase A/cAMP Response Element-Binding Protein (CREB)/p53 Axis. (2024/12/28) ♡
- Effect of CTMP1 gene on pulmonary fibrosis. (2024/12/28) ♡
- Lung dECM matrikine-based hydrogel reverses bleomycin-induced pulmonary fibrosis by suppressing M2 macrophage polarization. (2024/12/27) ♡
- Endothelial CD38-induced endothelial-to-mesenchymal transition is a pivotal driver in pulmonary fibrosis. (2024/12/27) ♡
- Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. (2024/12/27) ♡
- Prevalence of Gastroesophageal Reflux in Interstitial Lung Diseases Clinic. (2024/12/27) ♡
- Prognostic value of a composite physiologic index developed by adding bronchial and hyperlucent volumes quantified via artificial intelligence technology. (2024/12/24) ♡
- Investigates the Role of PANoptosis in Idiopathic Pulmonary Fibrosis and Potential Therapeutic Targets. (2024/12/24) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. (2024/12/23) ♡
- Integrating machine learning with bioinformatics for predicting idiopathic pulmonary fibrosis prognosis: developing an individualized clinical prediction tool. (2024/12/23) ♡
- Exercise-Induced Oxygen Desaturation and Outcomes After Nintedanib Therapy for Fibrosing Interstitial Lung Disease in Patients Without Dyspnea. (2024/12/23) ♡
- ANGPTL4 mediated mesothelial-mesenchymal transition in pulmonary fibrosis: a potential therapeutic target. (2024/12/20) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Persistent microbial infections and idiopathic pulmonary fibrosis - an insight into non-typeable Haemophilus influenza pathogenesis. (2024/12/20) ♡
- Overlapping Systemic Proteins in COVID-19 and Lung Fibrosis Associated with Tissue Remodeling and Inflammation. (2024/12/19) ♡
- Diagnostic and prognostic implications of family history of fibrotic interstitial lung diseases. (2024/12/18) ♡
- Computational deconvolution of cell type-specific gene expression in COPD and IPF lungs reveals disease severity associations. (2024/12/18) ♡
- Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis. (2024/12/18) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Intricate Relationship Between Pulmonary Fibrosis and Thrombotic Pathology: A Narrative Review. (2024/12/18) ♡
- Interstitial lung diseases with concomitant lung cancer: a data mining approach revealing a complex condition with gender- and immune-associated specific implications. (2024/12/17) ♡
- Proteomic profiling of bronchoalveolar lavage fluid uncovers protein clusters linked to survival in idiopathic forms of interstitial lung disease. (2024/12/16) ♡
- Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis. (2024/12/16) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The immune mechanisms of acute exacerbations of idiopathic pulmonary fibrosis. (2024/12/16) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases. (2024/12/15) ♡
- Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients. (2024/12/12) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Chemokine System as a Key Regulator of Pulmonary Fibrosis: Converging Pathways in Human Idiopathic Pulmonary Fibrosis (IPF) and the Bleomycin-Induced Lung Fibrosis Model in Mice. (2024/12/12) ♡
- Immune disease dialogue of chemokine-based cell communications as revealed by single-cell RNA sequencing meta-analysis. (2024/12/12) ♡
- Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis. (2024/12/10) ♡
- Multiscale computational model predicts how environmental changes and treatments affect microvascular remodeling in fibrotic disease. (2024/12/07) ♡
- Stage-Dependent Fibrotic Gene Profiling of WISP1-Mediated Fibrogenesis in Human Fibroblasts. (2024/12/05) ♡
- Treatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections-a systematic review and a meta-analysis. (2024/12/05) ♡
- Rapid LC-MS/MS Evaluation of Collagen and Elastin Crosslinks in Human and Mouse Lung Tissue with a Novel Bioanalytical Surrogate Matrix Approach. (2024/12/04) ♡
- Rectus femoris cross sectional area and timed up and go test potential useful of as a predictor of sarcopenia and mortality in idiopathic pulmonary fibrosis. (2024/12/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Circulating MicroRNAs in Idiopathic Pulmonary Fibrosis: A Narrative Review. (2024/12/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Aging Lung: Molecular Drivers and Impact on Respiratory Diseases-A Narrative Clinical Review. (2024/12/02) ♡
- Identification of Hub Genes and Prediction of Targeted Drugs for Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis. (2024/12/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.